Alan Huang
Overview
Explore the profile of Alan Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
4592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cottrell K, Briggs K, Tsai A, Tonini M, Whittington D, Gong S, et al.
J Med Chem
. 2025 Mar;
68(5):5097-5119.
PMID: 40035511
The gene encoding for MTAP is one of the most commonly deleted genes in cancer, occurring in approximately 10-15% of all human cancer. We have previously described the discovery of...
2.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
3.
Cottrell K, Whittington D, Briggs K, Jahic H, Ali J, Amor A, et al.
J Med Chem
. 2025 Feb;
68(4):4217-4236.
PMID: 39919252
Deletion of the gene leads to accumulation of the substrate of the MTAP protein, methylthioadenosine (MTA). MTA binds PRMT5 competitively with S-adenosyl-l-methionine (SAM), and selective inhibition of the PRMT5•MTA complex...
4.
Martires L, Ahronian L, Pratt C, Das N, Zhang X, Whittington D, et al.
Mol Cancer Ther
. 2025 Jan;
PMID: 39868490
Synthetic lethality approaches in BRCA1/2-mutated cancers have focused on poly(ADP-ribose) polymerase (PARP) inhibitors, which are subject to high rates of innate or acquired resistance in patients. Here, we used CRISPR/Cas9-based...
5.
Briggs K, Cottrell K, Tonini M, Tsai A, Zhang M, Whittington D, et al.
Transl Oncol
. 2025 Jan;
52:102264.
PMID: 39756156
TNG908 is a clinical stage PRMT5 inhibitor with an MTA-cooperative binding mechanism designed to leverage the synthetic lethal interaction between PRMT5 inhibition and MTAP deletion. MTAP deletion occurs in 10-15...
6.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2024 Oct;
635(8038):462-471.
PMID: 39385035
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of...
7.
Cottrell K, Briggs K, Whittington D, Jahic H, Ali J, Davis C, et al.
J Med Chem
. 2024 Apr;
67(8):6064-6080.
PMID: 38595098
It has been shown that PRMT5 inhibition by small molecules can selectively kill cancer cells with homozygous deletion of the gene if the inhibitors can leverage the consequence of deletion,...
8.
Philipson P, Huang A
Stat Comput
. 2023 May;
33(4):81.
PMID: 37220636
Count data that are subject to both under and overdispersion at some hierarchical level cannot be readily accommodated by classic models such as Poisson or negative binomial regression models. The...
9.
Wong J, Masson S, Huang A, Romm D, Fong M, Porter T, et al.
J Correct Health Care
. 2022 Nov;
28(6):368-371.
PMID: 36342953
Incarcerated clients experience high rates of opioid use disorder and overdose. It is critical that opioid agonist treatment (OAT) is provided in correctional facilities. However, few receive OAT due to...
10.
Simoneau A, Engel J, Bandi M, Lazarides K, Liu S, Meier S, et al.
Mol Cancer Ther
. 2022 Oct;
22(2):215-226.
PMID: 36228090
CRISPR Cas9-based screening is a powerful approach for identifying and characterizing novel drug targets. Here, we elucidate the synthetic lethal mechanism of deubiquitinating enzyme USP1 in cancers with underlying DNA...